Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03714906 · ClinicalTrials.gov registry record · NA

Stellate Ganglion Block in Head and Neck Cancer Surgery

A NA study, sponsored by Augusta University.

Terminated
Registry status
NA
Development phase
22
Enrollment target

NCT03714906: Clinical Trial NA study, sponsored by Augusta University.

NCT03714906 is a NA study that was terminated before completion, run by Augusta University. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03714906, a NA study, was terminated before completion, sponsored by Augusta University.

TERMINATED
Registry status
NA
Development phase
22 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate and reduce pain and improve quality of life in patients being treated for head and neck cancer with unilateral surgery. In this study, patients will be randomly assigned to receive either pre-operative stellate ganglion block or no pre-operative treatment. Blocks will be placed by a trained anesthesiologist using ultrasound guidance in the preoperative holding area prior to surgery. All patients will receive the same post-operative pain medication regimen with appropriate pain treatment as needed. Patients will be asked to fill out surveys prior to surgery, while in the hospital after surgery, and at each follow-up appointment for up to 24 months.

Primary Outcome

Validated pain survey in head and neck cancer patients

Interventions

  • PROCEDURE Stellate ganglion block

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2019-03-22
Est. Completion 2022-09-15
Phase NA
Augusta University

106 total trials

Why NCT03714906 stopped before completion

NCT03714906 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Stellate ganglion block is the first listed.

NCT03714906 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03714906 about?

NCT03714906 is a clinical study titled "Stellate Ganglion Block in Head and Neck Cancer Surgery". The purpose of this study is to evaluate and reduce pain and improve quality of life in patients being treated for head and neck cancer with unilateral surgery. In this study, patients will be randomly assigned to receive either pre-operative stellate ganglion block or no pre-operative treatment. Bl...

What is the current status of trial NCT03714906?

This trial is currently terminated. It is a NA study. The enrollment target is 22 participants. The study started on 2019-03-22. Estimated completion is 2022-09-15.

What interventions are being tested in trial NCT03714906?

The interventions under investigation include: Stellate ganglion block (PROCEDURE).

Who is sponsoring clinical trial NCT03714906?

This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03714906's enrollment target sits among peer trials

22 1756th of 2000 higher than 239 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03714906, the US trial registry maintained by the National Library of Medicine. NCT03714906 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.